Vicus Therapeutics

Vicus Therapeutics is an immuno-oncology company focused on developing innovative cancer treatments by transforming FDA-approved drugs into Precision Medicines. The company utilizes a data-driven discovery process to dampen tumor-promoting inflammation, restore immune function, and enhance treatment tolerance. Its lead product, VT-122, is the first multi-pathway neuro-immune modulator designed for cancer treatment. This drug combines a controlled-release formulation of propranolol and etodolac to target multiple signaling pathways involved in cancer progression. VT-122 has demonstrated promising results in clinical studies, including a Phase 2 trial for patients with advanced liver cancer, where it improved median overall survival by 4 to 7 months compared to standard care and reduced treatment-related toxicities. The product has also received Orphan Drug designations from the FDA for pancreatic, liver, and brain cancers. Vicus Therapeutics aims to address the dual trends of immunotherapy and Precision Medicines in the oncology market, providing more effective and tailored treatment options for patients.